AI Summary of Peer-Reviewed Research
This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. See full disclosure ↓
⚠️ This article summarizes published research and is intended for informational purposes only. It does not constitute medical advice or clinical guidance.
Publication Signals show what we were able to verify about where this research was published.MODERATECore publication signals for this source were verified. Publication Signals reflect the source’s verifiable credentials, not the quality of the research.
- ✔ Peer-reviewed source
- ✔ No retraction or integrity flags
Overview
Paternal use of valproate, an established human teratogen with known risks for maternal exposure during pregnancy, has not been comprehensively evaluated for associations with neurodevelopmental disorders in offspring when exposure occurs in fathers. This study examined whether paternal valproate use in the periconceptional period demonstrates associations with neurodevelopmental disorder risk in children.
Methods and approach
The investigation utilized population-based cohort data from Norway and Taiwan, enabling comparison across distinct geographic and healthcare system contexts. Paternal valproate exposure was defined as medication use within 90 days preceding conception. Neurodevelopmental disorder outcomes in offspring were assessed through registry or medical records. Multivariable adjustment for potential confounding variables was applied to isolate associations between paternal exposure and offspring outcomes.
Key Findings
Analysis of the Norwegian and Taiwanese cohorts did not demonstrate a statistically significant association between paternal valproate use within 90 days before conception and increased risk of neurodevelopmental disorders in offspring following adjustment for confounding factors. The null findings were consistent across both populations studied.
Implications
These findings suggest that paternal valproate use in the periconceptional period does not constitute a measurable risk factor for neurodevelopmental disorders in offspring, contrasting with established risks associated with maternal valproate exposure during pregnancy. The consistency of null associations across two independent cohorts with different demographic and healthcare characteristics provides reasonable epidemiological evidence against a paternal exposure pathway. Further investigation may be warranted to clarify whether specific neurodevelopmental phenotypes, dose exposures, or alternative exposure windows demonstrate different patterns.
Disclosure
- Research title: Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children
- Authors: Lin-Chieh Meng, Marleen M. H. J. van Gelder, Hui-Min Chuang, HC Lai, Li Chen, Fei-Yuan Hsiao, Hedvig M E Nordeng
- Publication date: 2026-02-24
- DOI: https://doi.org/10.1056/evidoa2500254
- OpenAlex record: View
- Image credit: Photo by ckstockphoto on Pixabay (Source • License)
- Disclosure: This post was generated by Claude (Anthropic). The original authors did not write or review this post.
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.